{"entity":{"id":"nct06005493","kind":"trial","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AZD5863 in pancreatic ductal adenocarcinoma, run by AstraZeneca, now recruiting.","summary":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06005493 by AstraZeneca, with 280 participants planned, started 2023-07-11 and due to reach its primary completion in 2027-07-16. Interventions recorded: AZD5863. Conditions listed: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06005493","url":"https://clinicaltrials.gov/study/NCT06005493"}],"tags":["ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["azd5863"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06005493","phase":"1/2","setting":"A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors","sponsor":"AstraZeneca","participation":[{"nct":"NCT06005493","source":"https://clinicaltrials.gov/study/NCT06005493","fetchedAt":"2026-10-07T16:54:05.353Z","studySha256":"32b4e94c37c4cba8765949930a797af6b210c9b5ed5107e09b9a2f4473c51c6e","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":392,"enrolmentType":"ESTIMATED","siteCount":25,"recruitingSiteCount":24,"countries":["China","France","Japan","Netherlands","South Korea","Taiwan","United Kingdom","United States"]}],"started":"2023-07-11","startedType":"actual","enrolled":280,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06005493/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"azd5863","kind":"drug","name":"AZD5863","route":"/drugs/azd5863/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}